| Literature DB >> 29137714 |
Abstract
How can we transform an immune desert into a 'hot tumor' that is prone to respond to anti-programmed death (PD)-1 immunotherapy? This might be possible by injecting an oncolytic virus, engineered to induce local immune stimulation, prior to anti-PD-1 therapy. A recent study demonstrated that this combination - evaluated in a Phase Ib metastatic melanoma clinical study - yields promising results.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29137714 DOI： 10.1016/j.molmed.2017.09.008
Source DB: PubMed Journal: Trends Mol Med ISSN： 1471-4914 Impact factor: 11.951